NCT03511690

Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment

Completed NA Last updated 25 April 2022

What this trial tests

NA trial testing BRCA-Gist in Hereditary Breast and Ovarian Cancer in 95 participants. Completed in 20 February 2022.

Timeline

1 July 2017

Primary endpoint
20 February 2022

20 February 2022

Quick facts

Lead sponsor	Georgetown University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	screening
Enrollment	95
Start date	1 July 2017
Primary completion	20 February 2022
Estimated completion	20 February 2022
Sites	4 locations across United States

Drugs / interventions tested

• BRCA-Gist

Conditions studied

• Hereditary Breast and Ovarian Cancer — all drugs for Hereditary Breast and Ovarian Cancer →

Sponsor

Georgetown University

Who can join

18 and older, female only, with Hereditary Breast and Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Participating in genetic cancer risk assessments (GCRA) for hereditary breast and ovarian cancer can inform treatment and risk management decisions and improve breast cancer outcomes. However, Latina and Black women underuse GCRA services, which may increase breast cancer disparities. This study will adapt and test the impact of an easily scalable novel Tutoring System intervention to enhance GCRA use and improve psychosocial outcomes in a clinical sample of underserved Latina and Black women at risk of hereditary breast and ovarian cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Artificial Intelligence in Oncology: A 10-Year ClinicalTrials.gov-Based Analysis Across the Cancer Control Continuum.
   Verma H, Mistry S, Jayam KV, Shrestha P, et al · · 2025 · PMID 41228330 · DOI 10.3390/cancers17213537